Pfizer said it made a renewed approach to AstraZeneca regarding a takeover valued at nearly $100 billion, but the U.K.-listed pharmaceutical firm had declined to engage in talks.
via WSJ.com: US Business http://ift.tt/1kbBPa4
via WSJ.com: US Business http://ift.tt/1kbBPa4
Nessun commento:
Posta un commento